NEW YORK, Feb. 08, 2017 -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against New Oriental Education & Technology Group Inc. (“New Oriental” or the “Company”) (NYSE:EDU) and certain of its officers, and is on behalf of a class consisting of all persons or entities who purchased or otherwise acquired New Oriental American Depositary Receipts (“ADRs”) between September 27, 2016 and December 1, 2016, inclusive (the “Class Period”). Such investors are advised to join this case by visiting the firm’s site: http://www.bgandg.com/edu.
This class action seeks to recover damages against Defendants for alleged violations of the federal securities laws under the Securities Exchange Act of 1934 (the “Exchange Act”).
The Complaint alleges that throughout the Class Period, Defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the Company’s business, operations, and prospects. Specifically, Defendants made false and/or misleading statements and/or failed to disclose that: (1) New Oriental engaged in college application fraud; and (2) consequently, New Oriental’s statements about its business, operations and prospects were materially false and misleading and/or lacked a reasonable basis at all relevant times.
On December 2, 2016, Reuters reported that New Oriental has been accused of college application fraud. The report describes how New Oriental engaged in “writing application essays and teacher recommendations, and falsifying high school transcripts.” Reuters also said that the American International Recruitment Council (AIRC) “will investigate the company in response to the report,” and that the AIRC’s president-elect said the allegations were “highly concerning.” Following this news, New Oriental stock dropped $6.99 per share, or 14.27%, to close at $42.00 on December 2, 2016.
A class action lawsuit has already been filed. If you wish to review a copy of the Complaint you can visit the firm’s site: http://www.bgandg.com/edu or you may contact Peretz Bronstein, Esq. or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC at 212-697-6484. If you suffered a loss in New Oriental you have until February 13, 2017 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.
Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique. Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients. In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm’s expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.
Contact: Bronstein, Gewirtz & Grossman, LLC Peretz Bronstein or Yael Hurwitz 212-697-6484 | [email protected]


GLP-1 Weight Loss Pills Set to Reshape Food and Fast-Food Industry in 2025
FTC Praises Instacart for Ending AI Pricing Tests After $60M Settlement
JPMorgan’s Top Large-Cap Pharma Stocks to Watch in 2026
Hyundai Recalls Over 51,000 Vehicles in the U.S. Due to Fire Risk From Trailer Wiring Issue
BP Nears $10 Billion Castrol Stake Sale to Stonepeak
Warner Bros Discovery Weighs Amended Paramount Skydance Bid as Netflix Takeover Battle Intensifies
Texas App Store Age Verification Law Blocked by Federal Judge in First Amendment Ruling
DOJ Reaches Settlement With Blackstone’s LivCor Over Alleged Rent Price-Fixing
Sanofi to Acquire Dynavax in $2.2 Billion Deal to Strengthen Vaccine Portfolio
Moore Threads Unveils New GPUs, Fuels Optimism Around China’s AI Chip Ambitions
ByteDance Plans Massive AI Investment in 2026 to Close Gap With U.S. Tech Giants
California Regulator Probes Waymo Robotaxi Stalls During San Francisco Power Outage
Italy Fines Apple €98.6 Million Over App Store Dominance
Nvidia to Acquire Groq in $20 Billion Deal to Boost AI Chip Dominance
John Carreyrou Sues Major AI Firms Over Alleged Copyrighted Book Use in AI Training
AstraZeneca’s LATIFY Phase III Trial of Ceralasertib Misses Primary Endpoint in Lung Cancer Study 



